1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
Letters to the Editor
You have free access to this content
Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis
Article first published online: 17 DEC 2012
DOI: 10.1111/apt.12142
© 2012 Blackwell Publishing Ltd
Additional Information
How to Cite
Yilmaz, Y. (2013), Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 37: 283. doi: 10.1111/apt.12142
Publication History
- Issue published online: 17 DEC 2012
- Article first published online: 17 DEC 2012
- Manuscript Accepted: 25 OCT 2012
- Manuscript Received: 23 OCT 2012
References
- 1, , , et al. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther 2012; 36: 1057–66.
- 2, , , et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27–33.
- 3, , , et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
- 4, , , et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837–44.
- 5, , , et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344–53.Direct Link: